By enGenes Biotech…
Subscribe to Supplier
Subscribe to Supplier
enGenes Biotech Joins CPHI Worldwide 2026 in Milan
Vienna, Austria: – Join enGenes Biotech at CPHI Worldwide 2026, taking place from October 6 to 8 in Milan, Italy. The recombinant proteins and plasmid DNA specialist CDMO returns to the show to reconnect with the pharma industry and open new conversations around its E. coli production platforms.
enGenes Biotech is attending as a visitor this year rather than exhibiting on its own stand, and will be available for meetings throughout the show via the official CPHI networking app.
Built for Innovators Who Want Their Own E. coli Process
For companies developing a target molecule and weighing up whether to build an E. coli production process in-house or continue outsourcing it, CPHI Worldwide is one of the few places to have that conversation directly with the people who design these platforms. enGenes is using Milan to meet exactly this audience: innovators exploring E. coli-based manufacturing routes, and potential licensees and partners for its technology platforms and wider product portfolio.
Two Products, One Bioprocessing Toolkit
Among the topics on the agenda will be enGenes’ recombinant Protein A affinity ligands, produced using its E. coli platform and aimed at resin and membrane manufacturers seeking a European supply source, and -eXrase, the company’s recombinant endonuclease for nucleic acid removal in bioprocessing, built to improve scalability, foam control and downstream processing in industrial fermentation.
Both sit alongside enGenes’ proprietary -eXpress™ E. coli expression platform, the technology behind the company’s work helping biopharma and industrial biotech partners cut production costs and move past the yield and solubility bottlenecks that so often slow recombinant protein and plasmid DNA development.
Representing enGenes in Milan will be Ophelia Gevaert, Business Development Manager, and Natalia Danielewicz, Senior Scientist.
About enGenes Biotech
enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.
enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-eXpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes- eXpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.
enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.
Find out more at: https://www.engenes.cc
About CPHI Worldwide Milan 2026
CPHI Worldwide is Europe’s flagship annual trade show for pharma ingredients, manufacturing technology and partner sourcing, bringing together the entire pharmaceutical supply chain under one roof. The event uses a hybrid model that combines one of Europe’s largest physical expos with an online dimension, extending networking and business opportunities beyond the show floor.
CPHI Worldwide 2026 runs from October 6-8 at Fiera Milano in Milan, Italy, and is organized by Informa, with further information at: https://www.cphi.com/europe/
Resources
Contact enGenes to set up meeting at CPHI Milan.
Related Articles
